Showing results (51-60 of 259) with videos related to
Sort By:
Pageof 26
Lung Cancer (Amsterdam, Netherlands)|June 16, 2014
Afatinib in the treatment of EGFR mutation-positive NSCLC--a network meta-analysisSanjay Popat, Tony Mok, James Chih-Hsin Yang, et al.BMC Cancer|October 11, 2011
INSPIRE: A phase III study of the BLP25 liposome vaccine (L-BLP25) in Asian patients with unresectable stage III non-small cell lung cancerYi-Long Wu, Keunchil Park, Ross A Soo, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 23, 2022
Osimertinib plus Selumetinib in EGFR-Mutated Non-Small Cell Lung Cancer After Progression on EGFR-TKIs: A Phase Ib, Open-Label, Multicenter Trial (TATTON Part B)James Chih-Hsin Yang, Yuichiro Ohe, Chao-Hua Chiu, et al.Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|December 24, 2016
Risk of Treatment-Related Toxicities from EGFR Tyrosine Kinase Inhibitors: A Meta-analysis of Clinical Trials of Gefitinib, Erlotinib, and Afatinib in Advanced EGFR-Mutated Non-Small Cell Lung CancerPei Ni Ding, Sarah J Lord, Val Gebski, et al.Journal of Nanobiotechnology|August 21, 2019
Improving the anticancer effect of afatinib and microRNA by using lipid polymeric nanoparticles conjugated with dual pH-responsive and targeting peptidesShu-Ting Hong, Huaching Lin, Chen-Shen Wang, et al.Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|December 2, 2014
Development of renal cysts after crizotinib treatment in advanced ALK-positive non-small-cell lung cancerYen-Ting Lin, Yu-Fen Wang, James Chih-Hsin Yang, et al.Targeted Oncology|February 7, 2019
Phase I Study of the Focal Adhesion Kinase Inhibitor BI 853520 in Japanese and Taiwanese Patients with Advanced or Metastatic Solid TumorsToshihiko Doi, James Chih-Hsin Yang, Kohei Shitara, et al.Molecular Oncology|October 30, 2012
MEK inhibitors reverse resistance in epidermal growth factor receptor mutation lung cancer cells with acquired resistance to gefitinibMing-Hung Huang, Jih-Hsiang Lee, Ya-Ju Chang, et al.The Oncologist|July 25, 2012
Survival following surgery with or without adjuvant chemotherapy for stage I-IIIA non-small cell lung cancer: an east asian population-based studyZhong-Zhe Lin, Wen-Yi Shau, Yu-Yun Shao, et al.Expert Review of Anticancer Therapy|March 20, 2013
Diarrhea associated with afatinib: an oral ErbB family blockerJames Chih-Hsin Yang, Noemi Reguart, Jana Barinoff, et al.Pageof 26